MedTrace Logo

PTX-200 and Carboplatin in Ovarian Cancer

NCT01690468 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-09-24

No results posted yet for this study

Summary

The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.

Conditions

Interventions

DRUG

Triciribine

Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.

DRUG

Carboplatin

Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.

Sponsors & Collaborators

  • Prescient Therapeutics, Ltd.

    lead INDUSTRY

Principal Investigators

  • Robert Wenham, MD · H. Lee Moffitt Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01690468 on ClinicalTrials.gov